Skip to main content

and
  1. Article

    Open Access

    Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature

    Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global...

    Johanna S. Song, Marianne Tawa, Nicole G. Chau, Thomas S. Kupper in BMC Cancer (2017)

  2. Article

    Open Access

    Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer

    Preclinical and clinical studies suggest potential synergy between high dose per fraction focal radiation and immunotherapy. However, conventionally fractionated radiation regimens in combination with concurre...

    Vishwajith Sridharan, Danielle N Margalit, Stephanie A Lynch in British Journal of Cancer (2016)

  3. Article

    Open Access

    Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?

    Patient selection for phase I trials (PIT) in oncology is challenging. A typical inclusion criterion for PIT is 'life expectancy > 3 months', however the 90 day mortality (90DM) and overall survival (OS) of pa...

    Nicole G Chau, Ana Florescu, Kelvin K Chan, Lisa Wang, Eric X Chen in BMC Cancer (2011)